RaySearch Laboratories AB (publ) (RSLBF) Stock Price & Analysis
RaySearch Laboratories AB (publ) (RSLBF) — price $20.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $666M.
Educational signal · not a buy or sell recommendation · How to read this
RaySearch Laboratories AB (publ) · RSLBF
RaySearch Laboratories AB (publ) develops and markets innovative software solutions for cancer treatment. Their RayStation system is used globally for advanced radiation therapy planning.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $20.00 | |
| Change on the day | 0.00% | |
| 52-week range | $16.49 – $27.61 | |
| Market capitalisation | $666M | — |
| Price / earnings (trailing) | 28.95 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for RaySearch Laboratories AB (publ) (RSLBF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is RaySearch Laboratories AB (publ) (RSLBF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. RaySearch Laboratories AB (publ) (RSLBF) is the company analyzed here. It employs 433 people and is led by Johan Lof. In Q3 FY2026 it reported revenue of kr373M and net income of kr60M. The market values it at $666M.
What do the latest results show for RaySearch Laboratories AB (publ) (RSLBF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of kr373M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | kr373M | kr60M | kr1.81 (diluted) |
| Q2 FY2026 | kr270M | kr19M | kr0.57 (diluted) |
| Q1 FY2026 | kr289M | kr53M | kr1.55 (diluted) |
| Q4 FY2025 | kr375M | kr69M | kr2.00 (diluted) |
What are the financial strengths and risks for RaySearch Laboratories AB (publ) (RSLBF)?
Short answer · as of
The distress and quality screens read Altman Z 4.84 · Piotroski F 6. Trailing ratios: ROE 22.6% · ROA 11.3% · current ratio 1.32 · earnings yield 3.5% · free-cash-flow yield 7.0%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RSLBF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RSLBF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about RaySearch Laboratories AB (publ) (RSLBF)?
RaySearch Laboratories AB (publ) Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the RSLBF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is RSLBF a good stock to buy?
Stock Expert AI does not rate RSLBF buy, sell or hold. RaySearch Laboratories AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RSLBF stock price today?
The last price recorded for RaySearch Laboratories AB (publ) (RSLBF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about RSLBF stock?
Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and competitive landscape before making any investment decisions. Key valuation metrics to consider include the company's P/E ratio, profit margin, and gross margin.
What are the key factors to evaluate for RSLBF?
Evaluate RSLBF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Strengthening partnerships with leading cancer centers: RaySearch can strengthen its partnerships with leading cancer centers and hospitals to drive adoption of its software solutions. Not financial advice.
How frequently does RSLBF data refresh on this page?
RSLBF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RSLBF's recent stock price performance?
RaySearch Laboratories AB (publ) (RSLBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative software solutions for cancer treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RSLBF overvalued or undervalued right now?
The trailing P/E of RaySearch Laboratories AB (publ) (RSLBF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RSLBF before investing?
Before investing in RaySearch Laboratories AB (publ) (RSLBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com